Position
Renaissance Technologies in Vaxcyte, Inc.
Back to the book · All holders of PCVX
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $392$58.11 → $58.13
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 65.2K | $3.01M | — | — | — | 0.0% |
| Q1 2026 | 54.7K | $3.18M | $58.11 | $655.2K | −$483.4K | 0.0% |
| Q2 2026 | 19.6K | $1.14M | $58.13 | $392 | −$2.04M | 0.0% |